U.S. Markets close in 3 hrs 5 mins
  • S&P 500

    4,522.45
    -54.65 (-1.19%)
     
  • Dow 30

    34,496.52
    -143.27 (-0.41%)
     
  • Nasdaq

    15,016.73
    -364.59 (-2.37%)
     
  • Russell 2000

    2,165.83
    -40.50 (-1.84%)
     
  • Crude Oil

    67.10
    +0.60 (+0.90%)
     
  • Gold

    1,781.00
    +18.30 (+1.04%)
     
  • Silver

    22.44
    +0.12 (+0.56%)
     
  • EUR/USD

    1.1311
    +0.0005 (+0.0452%)
     
  • 10-Yr Bond

    1.3870
    -0.0610 (-4.21%)
     
  • Vix

    30.49
    +2.54 (+9.09%)
     
  • GBP/USD

    1.3238
    -0.0064 (-0.4819%)
     
  • USD/JPY

    112.8120
    -0.3970 (-0.3507%)
     
  • BTC-USD

    55,005.77
    -1,557.45 (-2.75%)
     
  • CMC Crypto 200

    1,396.59
    -45.17 (-3.13%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

New Strong Sell Stocks for September 8th

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Adverum Biotechnologies, Inc. ADVM is a clinical-stage gene therapy company. The Zacks Consensus Estimate for its current year earnings has been revised 16.3% downward over the last 30 days.

JetBlue Airways Corporation JBLU is a provider of air transportation services. The Zacks Consensus Estimate for its current year earnings has been revised 0.2% downward over the last 30 days.

Kadmon Holdings, Inc. KDMN is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 10% downward over the last 30 days.

Alpine Immune Sciences, Inc. ALPN is focussed on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.

Provention Bio, Inc. PRVB is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 37.7% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
JetBlue Airways Corporation (JBLU) : Free Stock Analysis Report
 
Adverum Biotechnologies, Inc. (ADVM) : Free Stock Analysis Report
 
Kadmon Holdings, Inc. (KDMN) : Free Stock Analysis Report
 
Nivalis Therapeutics, Inc. (ALPN) : Free Stock Analysis Report
 
Provention Bio, Inc. (PRVB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research